Cyclopropamitosenes: novel bioreductive anticancer agents--mechanism of action and enzymic reduction.

doi:10.1097/00001813-199406000-00016

Paper

Cyclopropamitosenes: novel bioreductive anticancer agents--mechanism of action and enzymic reduction.

Published Jun 1, 1994 · C. Moody, N. O'sullivan, I. Stratford

Anti-cancer drugs

Q3 SJR score

13

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

The mechanism of action of cyclopropamitosenes, novel bioreductive anticancer agents, has been investigated using a unique combination of chemical and biochemical techniques. The compounds 4 function as reductively activated alkylating agents under chemical reducing conditions, and the biochemical experiments establish that the methoxy- and aziridinyl-derivatives 4a and 4b behave differently upon bioreduction.

Study Snapshot

Cyclopropamitosenes show potential as bioreductive anticancer agents due to their unique mechanism of action and enzymic reduction.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Cyclopropamitosenes: novel bioreductive anticancer agents--mechanism of action and enzymic reduction.

Sign up to use Study Snapshot

References

Citations

Stereoselective Synthesis of Fused Aziridines via One-Pot Sequential Decarboxylative Mannich Reaction and Oxidative C-H Amination of Cyclic Imines with β-Ketoacids.

This one-pot method allows for the stereoselective synthesis of fused aziridines with excellent diastereoselectivity.

Synthesis of cyclopropanes by Pd-catalyzed activation of alkyl C–H bonds

This study developed a novel synthesis of cyclopropanes using palladium-catalyzed C-H activation, enabling efficient access to cyclopropapyrrolo[1,2-a]indoles, analogues of mitomycin and cyclopropamitos

Synthesis of dimethyl substituted benzimidazoles containing cyclopropane fused onto five to eight membered [1,2-a]alicyclic rings and influence of methyl group substituents on cytotoxicity of benzimidazolequinones

Dimethyl group substituents significantly reduce the cytotoxicity of benzimidazolequinone towards human skin fibroblast cells.

Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential.

New synthetic quinones and inhibitors of NQO1 enzyme show potential as therapeutic agents against human pancreatic cancer.

Synthesis by radical cyclization and cytotoxicity of highly potent bioreductive alicyclic ring fused [1,2-a]benzimidazolequinones.

This study successfully synthesized highly potent bioreductive benzimidazolequinones, with the most potent being over 300 times more cytotoxic than mitomycin C, and modified the structure to decrease cytotoxicity and selectivity towards hypoxia.

Mechanisms of action of quinone-containing alkylating agents. I: NQO1-directed drug development.

NQO1-directed bioreductive drug development aims to selectively kill cancer cells by targeting high levels of NQO1 in tumors, with potential for future clinical trials.

Novel quinolinequinone antitumor agents: structure-metabolism studies with NAD(P)H:quinone oxidoreductase (NQO1).

Quinones with pyridine substituents show the best substrate activity for human NQO1, making them more toxic to NQO1-containing or expressing human colon carcinoma cells than NQO1 deficient cells.

Indolequinone antitumor agents: relationship between quinone structure and rate of metabolism by recombinant human NQO1.

Indolequinone antitumor agents with different functional groups show varying effects on metabolism by human NQO1 and toxicity towards nonsmall cell lung cancer cells.

EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group.

EO9 is a well-tolerated but inactive chemotherapy agent for advanced breast, gastric, pancreatic, and colorectal cancers at this dose and schedule.